Sirolimus 3mg Tablet

Sirolimus 3mg Tablet contains sirolimus, an immunosuppressive medicine and mechanistic target of rapamycin (mTOR) inhibitor. Sirolimus is primarily used in specialist transplant medicine to reduce immune activity and help prevent organ rejection following renal transplantation. It is also approved for the treatment of lymphangioleiomyomatosis (LAM) in applicable markets.

Important strength note: Current U.S. sirolimus tablet labeling identifies 0.5mg, 1mg, and 2mg tablets as marketed tablet strengths. A 3mg tablet should therefore be verified against the specific manufacturer's packaging, authorization, and market registration before being described as an authorized 3mg formulation or as “Generic Rapamune® 3mg.”

Product Information

Generic Name

Sirolimus

Strength

3mg

Drug Class

Immunosuppressant; mTOR Inhibitor

Active Ingredient

Sirolimus

Also Known As

Rapamycin

Dosage Form

Oral Tablet

Route

Oral

Prescription

Yes

Primary Specialist Use

Renal transplant immunosuppression

Other Approved Use

Lymphangioleiomyomatosis (LAM), where authorized

Therapeutic Drug Monitoring

Required in appropriate patients

Brand Reference

Rapamune® contains sirolimus; do not assume a 3mg tablet is an authorized generic equivalent without product-specific regulatory documentation.

Sirolimus for Kidney Transplant Immunosuppression

After renal transplantation, the immune system can identify the transplanted organ as foreign. Immunosuppressive medicines such as sirolimus help reduce this immune response.

Sirolimus may be used as part of a broader immunosuppressive regimen involving other medicines. Treatment must be individualized by a transplant specialist, and blood concentrations are monitored in appropriate patients.

Current U.S. labeling emphasizes that sirolimus should be used by physicians experienced in immunosuppressive therapy and renal-transplant management.

Sirolimus and Rapamune®

Sirolimus is the generic active ingredient, while Rapamune® is a branded sirolimus product.

Therefore:

• Sirolimus = generic active ingredient
• Rapamune® = branded sirolimus product
• Generic sirolimus tablets = products containing sirolimus that have been appropriately authorized in their respective markets

However, the currently identified U.S. tablet strengths are 0.5mg, 1mg, and 2mg. A 3mg tablet should not automatically be described as “Generic Rapamune® 3mg” without documentation confirming its regulatory status and equivalence.

Monitoring During Treatment

Patients receiving sirolimus may require monitoring of:

• Sirolimus blood concentrations
• Kidney function
• Liver function
• Complete blood count
• Lipid levels
• Blood pressure
• Urinary protein
• Infection symptoms
• Wound healing
• Respiratory symptoms

Therapeutic drug monitoring is particularly important because sirolimus has clinically significant pharmacokinetic variability and numerous potential drug interactions.

Availability & Ordering

Commercial searches for this product may include Sirolimus 3mg Tablet, Sirolimus 3mg, Buy Sirolimus 3mg Online, Sirolimus 3mg Price, Sirolimus 3mg Tablet Online Pharmacy, Sirolimus Immunosuppressant, Sirolimus mTOR Inhibitor, and Sirolimus Transplant Medicine.

Because 3mg is not among the tablet strengths identified in current U.S. labeling, buyers and healthcare professionals should verify the manufacturer, strength, registration status, packaging, and country-specific authorization before purchasing a product marketed as Sirolimus 3mg Tablet.

Prescription medicines should only be obtained from appropriately regulated pharmacies or suppliers and used under qualified medical supervision.

How it works

Sirolimus is an mTOR inhibitor. It binds to FKBP-12 and inhibits mTORC1 signaling, a pathway involved in cellular growth and T-lymphocyte activation and proliferation.

By suppressing T-cell activity, sirolimus reduces the immune response that can contribute to rejection of a transplanted kidney.

Sirolimus is primarily used as an immunosuppressive medicine in transplant care.

Approved uses of sirolimus tablets include:

• Prevention of organ rejection in patients receiving renal transplants
• Treatment of lymphangioleiomyomatosis (LAM) in applicable products and jurisdictions
• Specialist immunosuppressive treatment according to an individualized transplant regimen

Current U.S. labeling specifically indicates sirolimus for prevention of organ rejection in patients aged 13 years or older receiving renal transplants and for treatment of LAM.

Sirolimus produces substantial immunosuppression and should be used under specialist medical supervision.

Important risks include:

• Increased susceptibility to bacterial, viral, and fungal infections
• Increased risk of lymphoma and certain malignancies, particularly skin cancer
• Hyperlipidemia
• Reduced blood-cell counts
• Fluid accumulation and edema
• Impaired wound healing
• Proteinuria
• Decline in renal function
• Interstitial lung disease or non-infectious pneumonitis
• Hypersensitivity reactions
• Angioedema
• Potential embryo-fetal toxicity

The current U.S. label also warns that sirolimus is not recommended for liver or lung transplant patients because safety and efficacy have not been established and serious transplant-specific complications have been reported.

Drug Interactions

Sirolimus has clinically important interactions with medicines and substances that affect metabolic and transporter pathways, particularly CYP3A4 and P-glycoprotein.

The current prescribing information also identifies cannabidiol as a potential interaction requiring consideration of therapeutic drug monitoring and dose adjustment. Patients should provide their transplant specialist or pharmacist with a complete list of prescription medicines, over-the-counter products, supplements, and herbal preparations.